Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal-Reference-Cited by-同舟云学术

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal

Published:2019-06 Issue:6 Volume:180 Page:1348-1351
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Al‐Janabi A.¹^ORCID,Jabbar‐Lopez Z.K.²,Griffiths C.E.M.¹,Yiu Z.Z.N.¹^ORCID

Affiliation:

1. Dermatology Centre Salford Royal NHS Foundation Trust The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre Manchester U.K.

2. Unit for Population‐Based Dermatology Research St John's Institute of Dermatology King's College London & Guy's and St Thomas’ NHS Foundation Trust London U.K.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.17624

Reference15 articles.

1. IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

2. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris

3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

4. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased synthesis and intestinal expression of IL-39 in patients with inflammatory bowel disease;Immunologic Research;2023-11-16

2. Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing;Clinical, Cosmetic and Investigational Dermatology;2023-01

3. From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery;Frontiers in Immunology;2021-02-17

4. Recent advances in inflammatory bowel disease therapy;European Journal of Pharmaceutical Sciences;2020-12

5. Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis;International Journal of Molecular Sciences;2020-11-19